ES2534400T3 - Uso de ciclopamina en el tratamiento de carcinoma de células basales y otros tumores - Google Patents
Uso de ciclopamina en el tratamiento de carcinoma de células basales y otros tumores Download PDFInfo
- Publication number
- ES2534400T3 ES2534400T3 ES10163813.8T ES10163813T ES2534400T3 ES 2534400 T3 ES2534400 T3 ES 2534400T3 ES 10163813 T ES10163813 T ES 10163813T ES 2534400 T3 ES2534400 T3 ES 2534400T3
- Authority
- ES
- Spain
- Prior art keywords
- cyclopamine
- cells
- medicament
- tumor
- ccbs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- QASFUMOKHFSJGL-LAFRSMQTSA-N Cyclopamine Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H](CC2=C3C)[C@@H]1[C@@H]2CC[C@@]13O[C@@H]2C[C@H](C)CN[C@H]2[C@H]1C QASFUMOKHFSJGL-LAFRSMQTSA-N 0.000 title claims abstract description 70
- QASFUMOKHFSJGL-UHFFFAOYSA-N cyclopamine Natural products C1C=C2CC(O)CCC2(C)C(CC2=C3C)C1C2CCC13OC2CC(C)CNC2C1C QASFUMOKHFSJGL-UHFFFAOYSA-N 0.000 title claims abstract description 69
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 39
- 206010004146 Basal cell carcinoma Diseases 0.000 title claims description 7
- 238000011282 treatment Methods 0.000 title abstract description 16
- 230000006907 apoptotic process Effects 0.000 claims abstract description 22
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 22
- 239000003814 drug Substances 0.000 claims abstract description 18
- 230000002265 prevention Effects 0.000 claims abstract description 4
- 241000027355 Ferocactus setispinus Species 0.000 claims abstract 3
- 230000004069 differentiation Effects 0.000 claims description 14
- 239000006071 cream Substances 0.000 claims description 12
- 230000000699 topical effect Effects 0.000 claims description 5
- 239000007933 dermal patch Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 230000019491 signal transduction Effects 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 238000013270 controlled release Methods 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 239000000017 hydrogel Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 230000002601 intratumoral effect Effects 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 238000007910 systemic administration Methods 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 230000008034 disappearance Effects 0.000 abstract description 4
- 230000011664 signaling Effects 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 57
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 description 16
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 description 16
- 229940068196 placebo Drugs 0.000 description 15
- 239000000902 placebo Substances 0.000 description 15
- 210000002615 epidermis Anatomy 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 244000060234 Gmelina philippensis Species 0.000 description 11
- 230000001640 apoptogenic effect Effects 0.000 description 10
- 208000031513 cyst Diseases 0.000 description 9
- 238000002372 labelling Methods 0.000 description 9
- 108010069873 Patched Receptors Proteins 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 102000000017 Patched Receptors Human genes 0.000 description 7
- 210000003780 hair follicle Anatomy 0.000 description 7
- 230000005778 DNA damage Effects 0.000 description 6
- 231100000277 DNA damage Toxicity 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 230000002093 peripheral effect Effects 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 102000004856 Lectins Human genes 0.000 description 5
- 108090001090 Lectins Proteins 0.000 description 5
- 239000002523 lectin Substances 0.000 description 5
- 238000001959 radiotherapy Methods 0.000 description 5
- 206010011732 Cyst Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 231100000804 nongenotoxic Toxicity 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 3
- 240000003864 Ulex europaeus Species 0.000 description 3
- 235000010730 Ulex europaeus Nutrition 0.000 description 3
- 231100000024 genotoxic Toxicity 0.000 description 3
- 230000001738 genotoxic effect Effects 0.000 description 3
- 230000002055 immunohistochemical effect Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 210000005170 neoplastic cell Anatomy 0.000 description 3
- 238000011275 oncology therapy Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 208000007660 Residual Neoplasm Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000000270 basal cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 210000001061 forehead Anatomy 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 238000002991 immunohistochemical analysis Methods 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 230000006882 induction of apoptosis Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000031146 intracellular signal transduction Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 230000037311 normal skin Effects 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- 206010062804 Basal cell naevus syndrome Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 239000012623 DNA damaging agent Substances 0.000 description 1
- 206010061619 Deformity Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000031995 Gorlin syndrome Diseases 0.000 description 1
- 102000003693 Hedgehog Proteins Human genes 0.000 description 1
- 108090000031 Hedgehog Proteins Proteins 0.000 description 1
- 241000234435 Lilium Species 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 102000013380 Smoothened Receptor Human genes 0.000 description 1
- 108010090739 Smoothened Receptor Proteins 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000489524 Veratrum californicum Species 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000025194 apoptotic cell clearance Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000011393 cytotoxic chemotherapy Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 238000013115 immunohistochemical detection Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 201000005734 nevoid basal cell carcinoma syndrome Diseases 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/TR2001/000027 WO2002078703A1 (en) | 2001-07-02 | 2001-07-02 | Use of cyclopamine in the treatment of basal cell carcinoma and other tumors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2534400T3 true ES2534400T3 (es) | 2015-04-22 |
Family
ID=21619326
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10163813.8T Expired - Lifetime ES2534400T3 (es) | 2001-07-02 | 2001-07-02 | Uso de ciclopamina en el tratamiento de carcinoma de células basales y otros tumores |
| ES01952097T Expired - Lifetime ES2250434T3 (es) | 2001-07-02 | 2001-07-02 | Utilizacion de ciclopamina en el tratamiento del carcinoma de celulas basales y de otros tumores. |
| ES02736467T Expired - Lifetime ES2246011T3 (es) | 2001-07-02 | 2002-04-19 | Utilizacion de ciclopamina para la preparacion de un medicamento para el tratamiento de la psoriaris. |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES01952097T Expired - Lifetime ES2250434T3 (es) | 2001-07-02 | 2001-07-02 | Utilizacion de ciclopamina en el tratamiento del carcinoma de celulas basales y de otros tumores. |
| ES02736467T Expired - Lifetime ES2246011T3 (es) | 2001-07-02 | 2002-04-19 | Utilizacion de ciclopamina para la preparacion de un medicamento para el tratamiento de la psoriaris. |
Country Status (14)
| Country | Link |
|---|---|
| EP (4) | EP2862570A1 (OSRAM) |
| JP (3) | JP2004536045A (OSRAM) |
| KR (1) | KR20090125833A (OSRAM) |
| CN (2) | CN1525859B (OSRAM) |
| AT (2) | ATE305300T1 (OSRAM) |
| AU (1) | AU2001272892B8 (OSRAM) |
| BR (1) | BR0117063A (OSRAM) |
| CA (1) | CA2452151C (OSRAM) |
| DE (2) | DE60113733T2 (OSRAM) |
| DK (2) | DK1401438T3 (OSRAM) |
| ES (3) | ES2534400T3 (OSRAM) |
| PT (1) | PT1411938E (OSRAM) |
| RU (1) | RU2312661C2 (OSRAM) |
| WO (2) | WO2002078703A1 (OSRAM) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6984522B2 (en) | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
| US8044259B2 (en) | 2000-08-03 | 2011-10-25 | The Regents Of The University Of Michigan | Determining the capability of a test compound to affect solid tumor stem cells |
| EP2862570A1 (en) * | 2001-07-02 | 2015-04-22 | Sinan Tas | Use of cyclopamine in the treatment of basal cell carcinoma and other tumors |
| EP1411938B1 (en) * | 2001-07-02 | 2005-07-06 | Tas, Sinan | Use of cyclopamine for the manufacture of a medicament for the treatemnt of psoriasis |
| US20170326118A1 (en) | 2001-07-02 | 2017-11-16 | Sinan Tas | Drug treatment of tumors wherein hedgehog/smoothened signaling is utilized for inhibition of apoptosis of tumor cells |
| US8653083B2 (en) | 2005-08-22 | 2014-02-18 | The Johns Hopkins University | Hedgehog pathway antagonists to treat disease |
| EP2511298B1 (en) | 2005-10-31 | 2019-01-16 | Oncomed Pharmaceuticals, Inc. | Compositions and Methods for Treating Cancer based on human FZD receptors |
| US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
| WO2008070357A2 (en) * | 2006-10-31 | 2008-06-12 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Smoothened polypeptides and methods of use |
| TWI433674B (zh) | 2006-12-28 | 2014-04-11 | Infinity Discovery Inc | 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類 |
| WO2008092002A2 (en) | 2007-01-24 | 2008-07-31 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing pancreatic cancer |
| WO2008109184A1 (en) * | 2007-03-07 | 2008-09-12 | Infinity Pharmaceuticals, Inc. | Heterocyclic cyclopamine analogs and methods of use thereof |
| JP2010520310A (ja) * | 2007-03-07 | 2010-06-10 | インフィニティ・ディスカバリー・インコーポレイテッド | シクロパミンラクタム類似体及びその使用方法 |
| CN104059124A (zh) | 2007-12-27 | 2014-09-24 | 无限药品股份有限公司 | 立体选择性还原的方法 |
| CN101990542A (zh) * | 2008-02-08 | 2011-03-23 | 德克萨斯大学董事会 | 环巴胺酒石酸盐及其用途 |
| TWI506037B (zh) | 2008-09-26 | 2015-11-01 | Oncomed Pharm Inc | 捲曲結合劑類及彼等之用途 |
| US20110275576A1 (en) * | 2009-01-06 | 2011-11-10 | Utah State University | Carbohydrate-Cyclopamine Conjugates as Anticancer Agents |
| JP2009143963A (ja) * | 2009-03-25 | 2009-07-02 | Sinan Tas | 腫瘍細胞のアポトーシスを阻害するためにヘッジホッグ／スムーズンド信号を使用する腫瘍を治療するための製薬組成物 |
| JP6141015B2 (ja) | 2009-08-05 | 2017-06-07 | インフィニティ ファーマスーティカルズ、インク． | シクロパミン類似体の酵素によるアミノ基転移 |
| TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Ｗｎｔ拮抗劑及治療和篩選方法 |
| WO2011123785A2 (en) | 2010-04-01 | 2011-10-06 | Oncomed Pharmaceuticals, Inc. | Frizzled-binding agents and uses thereof |
| US9376447B2 (en) | 2010-09-14 | 2016-06-28 | Infinity Pharmaceuticals, Inc. | Transfer hydrogenation of cyclopamine analogs |
| EP2911691B1 (en) | 2012-10-23 | 2018-10-10 | OncoMed Pharmaceuticals, Inc. | Methods of treating neuroendocrine tumors using wnt pathway-binding agents |
| JP2016510411A (ja) | 2013-02-04 | 2016-04-07 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング |
| US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
| WO2015096654A1 (zh) * | 2013-12-26 | 2015-07-02 | 中国科学院上海生命科学研究院 | Shh信号通路特异性抑制剂的应用 |
| HRP20251395T1 (hr) | 2015-06-04 | 2026-02-13 | Sol-Gel Technologies Ltd. | Topikalne formulacije za isporuku spojeva inhibitora hedgehog signalnog puta i njihova uporaba |
| US20170231968A1 (en) * | 2016-02-11 | 2017-08-17 | PellePharm, Inc. | Method for relief of and treatment of pruritus |
| CN117940170A (zh) | 2021-09-13 | 2024-04-26 | 辛南·塔斯 | 有效干预人类衰老和衰老疾病及其效果 |
| CN114292279B (zh) * | 2022-01-07 | 2023-05-09 | 吉林省农业科学院 | 一种藜芦抗癌有效成分环杷明提取与分离方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5851993A (en) * | 1994-06-13 | 1998-12-22 | Biotie Therapies Ltd. | Suppression of tumor cell growth by syndecan-1 ectodomain |
| CA2326654C (en) * | 1998-04-09 | 2010-11-09 | Johns Hopkins University School Of Medicine | Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways |
| RU2232758C2 (ru) * | 1998-09-23 | 2004-07-20 | Рисерч Дивелопмент Фаундейшн | Токоферолы, токотриенолы и другие производные хромана и боковых цепей и способы лечения с их использованием |
| US6291516B1 (en) * | 1999-01-13 | 2001-09-18 | Curis, Inc. | Regulators of the hedgehog pathway, compositions and uses related thereto |
| ES2233383T3 (es) * | 1999-06-08 | 2005-06-16 | Lorantis Limited | Utilizacion terapeutica de un ihibidor de la via de señalizacion hedgehog. |
| CA2386190C (en) * | 1999-10-13 | 2009-04-14 | Johns Hopkins University School Of Medicine | Regulators of the hedgehog pathway, compositions and uses related thereto |
| AU1935801A (en) * | 1999-11-30 | 2001-06-12 | Curis, Inc. | Methods and compositions for regulating lymphocyte activity |
| CU23175A1 (es) * | 2000-07-17 | 2006-09-22 | Ct De Investigacion Y Desarrol | Formulacion liposomica de propionato de clobetasol |
| EP1411938B1 (en) * | 2001-07-02 | 2005-07-06 | Tas, Sinan | Use of cyclopamine for the manufacture of a medicament for the treatemnt of psoriasis |
| EP2862570A1 (en) * | 2001-07-02 | 2015-04-22 | Sinan Tas | Use of cyclopamine in the treatment of basal cell carcinoma and other tumors |
-
2001
- 2001-07-02 EP EP20140196071 patent/EP2862570A1/en not_active Withdrawn
- 2001-07-02 DK DK01952097T patent/DK1401438T3/da active
- 2001-07-02 EP EP05008758A patent/EP1561464A3/en not_active Withdrawn
- 2001-07-02 ES ES10163813.8T patent/ES2534400T3/es not_active Expired - Lifetime
- 2001-07-02 AU AU2001272892A patent/AU2001272892B8/en not_active Ceased
- 2001-07-02 EP EP01952097A patent/EP1401438B1/en not_active Revoked
- 2001-07-02 CN CN018234429A patent/CN1525859B/zh not_active Expired - Fee Related
- 2001-07-02 ES ES01952097T patent/ES2250434T3/es not_active Expired - Lifetime
- 2001-07-02 AT AT01952097T patent/ATE305300T1/de not_active IP Right Cessation
- 2001-07-02 WO PCT/TR2001/000027 patent/WO2002078703A1/en not_active Ceased
- 2001-07-02 EP EP10163813.8A patent/EP2216022B1/en not_active Expired - Lifetime
- 2001-07-02 JP JP2002576969A patent/JP2004536045A/ja active Pending
- 2001-07-02 BR BR0117063-5A patent/BR0117063A/pt active Search and Examination
- 2001-07-02 CA CA2452151A patent/CA2452151C/en not_active Expired - Fee Related
- 2001-07-02 DE DE60113733T patent/DE60113733T2/de not_active Expired - Lifetime
-
2002
- 2002-04-19 PT PT02736467T patent/PT1411938E/pt unknown
- 2002-04-19 ES ES02736467T patent/ES2246011T3/es not_active Expired - Lifetime
- 2002-04-19 AT AT02736467T patent/ATE299022T1/de not_active IP Right Cessation
- 2002-04-19 WO PCT/TR2002/000017 patent/WO2002078704A1/en not_active Ceased
- 2002-04-19 RU RU2004103074/15A patent/RU2312661C2/ru not_active IP Right Cessation
- 2002-04-19 DK DK02736467T patent/DK1411938T3/da active
- 2002-04-19 DE DE60204966T patent/DE60204966T2/de not_active Expired - Lifetime
- 2002-04-19 CN CNB02813429XA patent/CN1230169C/zh not_active Expired - Fee Related
-
2003
- 2003-03-17 KR KR1020097022024A patent/KR20090125833A/ko not_active Ceased
-
2010
- 2010-02-10 JP JP2010028010A patent/JP5424923B2/ja not_active Expired - Fee Related
-
2013
- 2013-09-18 JP JP2013193304A patent/JP2014028834A/ja not_active Ceased
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2250434T3 (es) | Utilizacion de ciclopamina en el tratamiento del carcinoma de celulas basales y de otros tumores. | |
| US7893078B2 (en) | Use of cyclopamine in the treatment of basal cell carcinoma and other tumors | |
| AU2001272892A1 (en) | Use of cyclopamine in the treatment of basal cell carcinoma and other tumors | |
| ES2207252T3 (es) | Uso de piperina y sus derivados para tratar trastornos de pigmentacion de la piel y cancer de piel. | |
| CA2596759C (en) | Local treatment of neurofibromas | |
| Huang et al. | Anticancer effects of gossypetin from Hibiscus sabdariffa in oral squamous cell carcinoma | |
| US10881702B2 (en) | Celastrol and derivatives thereof for the treatment of tumours and precancerous diseases of the skin | |
| JP2012236815A (ja) | ナス属（ｓｏｌａｎｕｍｇｅｎｕｓ）植物からの水溶性抽出物での炎症及び皮膚の光損傷の治療及び／又は予防、並びに皮膚の光防護 | |
| US20170326118A1 (en) | Drug treatment of tumors wherein hedgehog/smoothened signaling is utilized for inhibition of apoptosis of tumor cells | |
| JP2006516605A (ja) | 皮膚ライトニング剤のための向上した製剤 | |
| CN106074204A (zh) | 一种染料木素衍生物在美白领域的应用 | |
| RU2308948C2 (ru) | Применение циклопамина для лечения базально-клеточной эпителиомы (карциномы) и других опухолей | |
| CN113476432B (zh) | J147在制备治疗和/或预防色素增多性疾病的药物/化妆品的用途 | |
| CN112321483B (zh) | 2-芳基-3-吲哚取代乙酰胺类衍生物及其新用途 | |
| ES2974073T3 (es) | Uso terapéutico del afatinib en el cáncer | |
| CN121015680B (zh) | 野黄芩苷与红景天苷联合在治疗日光性皮炎中的应用 | |
| Soriano-Ursúa et al. | In vitro and in vivo evaluation of nanoliposomes loading quercetin and 3-bromopyruvate against glioma | |
| KR101587233B1 (ko) | 신규한 상처 치료, 상처 회복 또는 흉터 생성 억제용 피부 외용제 조성물 및 그를 이용한 상처 치료 방법 | |
| CN120154719A (zh) | Bcl2抑制剂在治疗先天性巨大黑痣中的应用 | |
| RU2698871C1 (ru) | Способ фотохимиотерапии витилиго | |
| US20120258937A1 (en) | Targeting Estrogen Receptors in the Treatment of Lymphangioleiomyomatosis | |
| WO2025222311A1 (zh) | Bcl2抑制剂在治疗先天性巨大黑痣中的应用 | |
| Footswitch et al. | Rotary Surgical System. | |
| KR20250108066A (ko) | 튜불린 저해제를 포함하는 병용요법을 이용한 피부 질환 예방 또는 치료용 조성물 | |
| WO2025183548A1 (es) | Composiciones que comprenden derivados acetilados de l-cisteina y 5-metil-1-fenil-2(1h)-piridona en nanopartículas y usos de las mismas |